POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic
Company reports revenues of EUR 13.4 million for the year ended December 31, 2021 As of December 31, 2021, cash and cash equivalents were EUR 32.3 million (USD 36.6 million) TWYMEEG
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic
As of December 31, 2021, cash and cash equivalents were EUR 32.3 million (USD 36.6 million) Company reports revenues of EUR 13.4 million for the year ended December 31, 2021 Results